logo

Crowdly

Browser

Додати до Chrome

BMS3031 - Molecular mechanisms of disease - S1 2026

Шукаєте відповіді та рішення тестів для BMS3031 - Molecular mechanisms of disease - S1 2026? Перегляньте нашу велику колекцію перевірених відповідей для BMS3031 - Molecular mechanisms of disease - S1 2026 в learning.monash.edu.

Отримайте миттєвий доступ до точних відповідей та детальних пояснень для питань вашого курсу. Наша платформа, створена спільнотою, допомагає студентам досягати успіху!

Certain mutations in the dystrophin gene disrupt the reading

frame, leading to little or no dystrophin production and the severe clinical

features seen in Duchenne muscular dystrophy (DMD). However, when the reading

frame is preserved—even if parts of the protein are missing—muscle function is

partially maintained, as observed in Becker muscular dystrophy.

How do antisense oligonucleotide therapies exploit this

difference to improve outcomes in patients with DMD?

Переглянути це питання

Eli Lilly decided to test all four lead compounds in Phase I clinical trials and the following pharmacokinetic parameters were determined.

Table 4: Pharmacokinetic properties of lead compounds as determined in Phase I clinical trials

 

Plasma half-life (hours)

Volume of distribution (L/kg)

Metabolic pathway

Adverse effects

EL-10

33

25

CYP3A4, CYP2C9

Arrhythmia

EL-11

98

40

CYP1A2, CYP2D6, CYP3A4, CYP2D6

Arrhythmia

EL-12

24

20

CYP2C19

Arrhythmia

EL-13

9

7

CYP3A4

Arrhythmia

Based on the data provided in Table 4, which of the compounds would be predicted to have the highest lipophilicity?

Переглянути це питання

Mutations in RPE65 impair the visual cycle in retinal cells,

leading to early-onset vision loss. An AAV-mediated gene therapy delivers a

functional copy of RPE65 to retinal tissue. This results in in sustained

protein expression and lasting visual improvement following a single administration;

even though no permanent changes are made to the patient’s genome.

Which characteristic of the AAV delivery system most

directly accounts for this durable therapeutic benefit?

Переглянути це питання

In pre-clinical studies, Eli Lilly tested four lead compounds for efficacy as selective serotonin reuptake inhibitors, using both in vitro and in vivo assays in rodents.

Initial studies investigated in vitro efficacy and selectivity.

Table 1: Assessment of in vitro efficacy of lead compounds in rodents

Inhibition of 5-HT uptake was assessed using synaptosomal preparations of rat brain, and affinity of binding to α1-adrenoceptors was assessed using membrane preparations of rat cerebral cortex.

Lead Compound

MW (g/mol)

Inhibition of  

5-HT uptake

IC50 (nM)

Binding to

α1 adrenoceptor

Ki (nM)

EL-05

329

0.4

27

EL-06

315

8

22

EL-07

309

2

2100

EL-08

277

24

160

IC50 = half maximal inhibitory concentration

Ki = measure of affinity

Based upon the data shown in Table 1, the rank order of 5-HT uptake carrier inhibition is BEST represented as:

Переглянути це питання

The beta-adrenoceptor antagonist, metoprolol is metabolised almost exclusively by CYP2D6.  

Which of the following would MOST LIKELY occur if metoprolol is taken at the same time as diphenhydramine (Benadryl), a known CYP2D6 inhibitor?

Переглянути це питання

The following information is relevant to this question:

Approximate volumes of body compartments

  • Plasma volume                           ~0.05 L/kg
  • Total extracellular volume           ~0.2 L/kg
  • Total body water                         ~0.55 L/kg

The Vd of a drug is determined to be 0.18 L/kg.  Which of the following statements is MOST consistent with this Vd?  The drug is:

Переглянути це питання

During lead optimisation, all lead compounds were evaluated for carcinogenic effects using the Ames test. 

Table 3:  Assessment of growth of his- salmonella in histidine free media in the absence or presence of liver extract.

Compound

his- salmonella colony growth

 

-Liver extract

+Liver extract

EL-01

No growth

No growth

EL-02

++

No growth

EL-03

No growth

++

EL-04

++

++

++ = colony growth

Based upon the data shown above in Table 3, which of the following compounds only has mutagenic potential in its active, non-metabolised form?

Переглянути це питання

During lead optimisation, all lead compounds were evaluated using the forced swim test in mice. 

Table 2: Assessment of in vivo efficacy of lead compounds in rodents

In the forced swim test, decreased immobility is considered to be associated with antidepressant activity 

Lead Compound

Forced swim test in mice

Time mice are immobile (s)

Placebo

154 ± 10

EL-10

(200µmol/kg)

73 ± 12

EL-11

(200µmol/kg)

                          146 ± 8

EL-12

(200µmol/kg)

117 ± 9

EL-13

(200µmol/kg)

162 ± 6

Values given as mean ± SEM

Based upon the data shown in Table 2, which of the compounds is MOST LIKELY to be effective in the treatment of patients with severe depression?

Переглянути це питання

A 75-year-old woman with poor kidney function is prescribed

a painkiller that is normally removed from the body by renal clearance. The

doctor decides to give the drug less frequently than the standard dosing schedule.

Why is it appropriate to increase the time between

doses in this patient?

Переглянути це питання

In pre-clinical studies, Eli Lilly tested four lead compounds for efficacy as selective serotonin reuptake inhibitors, using both in vitro and in vivo assays in rodents.

Initial studies investigated in vitro efficacy and selectivity.

Table 1: Assessment of in vitro efficacy of lead compounds in rodents

Inhibition of 5-HT uptake was assessed using synaptosomal preparations of rat brain, and affinity of binding to α1-adrenoceptors was assessed using membrane preparations of rat cerebral cortex.

Lead Compound

MW (g/mol)

Inhibition of  

5-HT uptake

IC50 (nM)

Binding to

α1 adrenoceptor

Ki (nM)

EL-01

324

1

20

EL-02

309

8

150

EL-03

306

2

100

EL-04

280

4

3500

IC50 = half maximal inhibitory concentration

Ki = measure of affinity

Based upon the data shown in Table 1 above and considering potential off-target actions, the compound MOST LIKELY to progress to the lead optimization phase of the drug discovery process is:

Переглянути це питання

Хочете миттєвий доступ до всіх перевірених відповідей на learning.monash.edu?

Отримайте необмежений доступ до відповідей на екзаменаційні питання - встановіть розширення Crowdly зараз!

Browser

Додати до Chrome